Filing Flows › Health Care › Enovis (ENOV)
Enovis (ENOV) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Enovis (ENOV) Q3 2026 earnings results →
Q3 2026 Revenue up 2% year over year to $559M · 1¢ of every $1 of revenue kept as net profit · operating margin 0.6%
Enovis made $559M in Q3 2026 (+2% Y/Y): Prevention & Recovery $285M, Reconstructive $273M. Operating margin 0.6%, net earnings $3.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $558.7M in Q3 2026, up 2% year over year and down 4% from the previous quarter. Prevention & Recovery was the largest line at 51% of revenue. Reconstructive added $15.4M year over year (up 6%), 156% of the total change. Prevention & Recovery declined 2%.
Gross margin was 60.8%, up 0.9 points from Q3 2025. Operating profit was $3.4M, a 0.6% margin (up 102.3 points year over year). Operating expenses fell 62% while revenue rose 2%. Net earnings were $3.1M. The effective tax rate was -96.6%.
Operating cash flow was $71.5M (down 13% year over year), 2092% of net income including minority interests. Non-cash charges added back $73.5M of depreciation and amortization and $7.8M of share-based compensation. Working capital and other items used $13.2M. Capital expenditures of $36.5M left free cash flow of $35.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $559M | +2% | 0.6% | $3.4M | $71.5M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $583M | +3% | 3.0% | −$1.0M | $75.0M |
| Q1 2026 | 10-Q | May 7, 2026 | $589M | +5% | 1.1% | −$8.4M | $24.0M |
| Q4 2025 | 10-K | Feb 26, 2026 | $576M | +3% | -87.2% | −$520M | $88.5M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $549M | +9% | -101.7% | −$571M | $82.6M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $565M | +8% | -3.0% | −$36.5M | $47.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $559M | +8% | -8.4% | −$55.7M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Enovis
Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system (“EGX”), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.
In its own words, from its 10-K, filed Feb 26, 2026.
Enovis against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +9%. Operating margin: 0.6% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
| INGN Inogen | Q2 2026 | $95.1M | +3% | -5.4% |
Source: Enovis 10-Q on SEC EDGAR · CIK 1420800 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Guidance and outlook
13F: who owns ENOV and who is buying
More on ENOV
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results